Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.
NCT04084665 · Rockefeller University · EARLY_PHASE1 · withdrawn · last registry update 2020-06-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “COVID-19 Pandemic” | – | Registry record, Rockefeller University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL12B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-05-26Also stopped (terminated): AstraZeneca, Brazikumab IV Infusion + Brazikumab SC Injection (NCT02574637)
- 2021-05-19Results posted on the registry: Sun Pharmaceutical Industries Limited, SUNPG1623 I + SUNPG1623 II (NCT02980692)
- 2021-05-11Phase 3 first posted: Janssen Research & Development, LLC, Guselkumab + Placebo (NCT04882098)
- 2021-05-11Results posted on the registry: AbbVie, Risankizumab (NCT03875508)
- 2021-05-06Also stopped (withdrawn): Eli Lilly and Company, Mirikizumab IV + Mirikizumab SC (NCT04469062)
- 2021-04-27Phase 3 first posted: AbbVie, Risankizumab (NCT04862286)
- 2021-04-14Phase 3 first posted: Eli Lilly and Company, Mirikizumab + Mirikizumab (NCT04844606)
- 2021-03-30Results posted on the registry: Eli Lilly and Company, Mirikizumab + Placebo (NCT03535194)
- 2021-03-16Results posted on the registry: AbbVie, Risankizumab + Placebo solution for risankizumab (NCT03875482)
- 2021-02-25Results posted on the registry: Novartis Pharmaceuticals, a drug against IL12B (NCT03553823)
- 2021-02-21Results posted on the registry: Sun Pharmaceutical Industries Limited, SUNPG1622 I dose + Placebo dose (NCT02980705)
- 2021-01-19Phase 3 first posted: AbbVie, Placebo for Risankizumab + Risankizumab (NCT04713592)
- 2020-11-05Results posted on the registry: Janssen Research & Development, LLC, Guselkumab + Placebo (NCT03158285)
- 2020-10-14Results posted on the registry: Janssen Research & Development, LLC, Guselkumab + Ustekinumab (NCT02319759)
- 2020-10-14Results posted on the registry: Janssen Research & Development, LLC, Guselkumab + Placebo (NCT03162796)
- 2020-09-25Results posted on the registry: Eli Lilly and Company, Mirikizumab + Placebo (NCT03482011)
- 2020-08-24Phase 3 first posted: AbbVie, Risankizumab + Risankizumab (NCT04524611)
- 2020-08-10Phase 3 first posted: University of Miami, Advanced therapy only without dietary intervention (NCT04505410)
- 2020-07-28Results posted on the registry: Eli Lilly and Company, Ixekizumab + Guselkumab (NCT03573323)
- 2020-07-13Phase 3 first posted: Eli Lilly and Company, Mirikizumab IV + Mirikizumab SC (NCT04469062)
- 2020-06-30Phase 3 first posted: AbbVie, Risankizumab + Placebo (NCT04451720)
- 2020-06-18Results posted on the registry: Eli Lilly and Company, Mirikizumab + Placebo (NCT02899988)
- 2020-06-17Phase 3 first posted: AbbVie, Risankizumab + Ustekinumab (NCT04435600)
- 2020-05-29Results posted on the registry: Eli Lilly and Company, Mirikizumab + Placebo (NCT02589665)
- 2020-05-21Phase 3 first posted: Janssen Pharmaceutical K.K., Guselkumab (NCT04397263)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision